Form 4: Marker Therapeutics Director Granted Stock Options

Marker Therapeutics Director Steve Elms received grants of 221,741 stock options for his service in 2024 and 2025.

Summary

• Steve Elms, a Director of Marker Therapeutics, Inc. (MRKR), was granted a total of 221,741 stock options.
• The grants occurred on November 17, 2025, with an exercise price of $0.9548 per share, which was the closing price on the grant date.
• One grant was for 84,411 stock options, representing the remaining options due for his service as a director for the year 2024 under the Company's 2020 Omnibus Stock Ownership Plan.
• A previous grant of 30,000 shares for 2024 service was made on February 12, 2025.
• The second grant was for 137,330 stock options, for his service as a director for the year 2025 under the same plan.
• Both sets of options vest on the anniversary of the grant date and have an expiration date of November 17, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction related to director compensation. While not indicative of immediate operational performance, it reflects standard corporate governance and aligns director interests with shareholders, which is a slight positive.

Positives

• The stock option grants align the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The grants represent routine compensation for director service, indicating stable corporate governance practices.

Future Outlook

The stock option grants are intended to incentivize the director's long-term commitment and performance, aligning their interests with the future stock performance of Marker Therapeutics, Inc. The vesting schedule ties the realization of value to continued service.

Industry Context

The granting of stock options to directors is a standard practice in the biotechnology and broader public company sectors. It serves as a key component of executive and director compensation packages, designed to attract and retain talent while aligning leadership's financial incentives with shareholder value creation.

Comparison to Industry Standards

• The filing details routine director compensation through stock option grants, a standard practice in corporate governance.
• This Form 4 does not provide specific comparable company data, projects, or results to benchmark against global industry standards.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholder value, potentially leading to more focused long-term decision-making. However, future exercise of options could lead to minor dilution.

Next Steps

• The granted options will vest on the anniversary of the grant date, November 17, 2025, over their respective vesting periods.

Key Dates

Keywords

Marker Therapeutics, MRKR, stock options, director compensation, insider transaction, Form 4, equity compensation